Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Razumab 2.3mg Injection
Manufacturer/Marketed By : INTAS PHARMACEUTICALS LTD
$169.71 $135.77
Razumab 2.3mg injection, contains the active ingredient Ranibizumab. It is an anti-neovascularisation agent in the class of medications called vascular endothelial growth factor A (VEGF-A) antagonists. It is used in...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
RANIBIZUMAB
Active Pharmaceutical Ingredient
Razumab 2.3mg Injection
169,71$
135,77$
Razumab 2.3mg injection, contains the active ingredient Ranibizumab. It is an anti-neovascularisation agent in the class of medications called vascular endothelial growth factor A (VEGF-A) antagonists. It is used in adults to treat several eye diseases causing vision impairment. It is used to treat wet age-related macular degeneration (AMD, a persistent eye disease that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities). Razumab 2.3mg injection is also used to treat myopic choroidal neovascularization (mCNV; a complication in near-sighted people where new blood vessels can grow in the back of the eye), and to treat macular edema after retinal vein occlusion (an eye disease caused by blockage of blood flow from the eye that leads to blurry vision and vision loss). It is also used to treat diabetic macular edema (an eye disease caused by diabetes that can lead to vision loss) and diabetic retinopathy (damage to the eyes caused by diabetes). Do not use Razumab 2.3mg injection if you are allergic to Ranibizumab or other ingredients of this medicine. Do not take this medicine if you have an infection in or around your eye and if you have pain or redness in your eye. Inform your doctor immediately if you develop symptoms such as eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in your vision, or increased sensitivity to light. Inform your doctor if you have a prior history of eye conditions or eye treatments or had a stroke before initiating the treatment.
Active Pharmaceutical Ingredient
Uses
• Age-related macular degeneration
• Macular edema
• Diabetic macular edema and retinopathy
• Myopic choroidal neovascularization
• Retinal vein occlusion
Benefits
Razumab 2.3mg injection specifically recognizes and binds to a protein called human vascular endothelial growth factor A (VEGF-A) present in the eye. In excess, VEGF-A causes abnormal blood vessel growth and swelling in the eye, leading to impairment of vision in certain eye diseases. This medicine can block its actions and prevent this abnormal growth and swelling. This injection can help to stabilize and improve your vision.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Most Common Side Effects
• Tear of the layer in the back of the eye
• Flashes of light in the eye
• Temporary loss of sight
• Clouding of lens
• Infection of the eyeball
Common Side Effects
• Pain and swelling in the eye
• Bleeding in the eye
• Blurred vision
• Urinary tract infection
• Skin rashes
• Discharge from the eye
How To Use
Razumab 2.3mg injection is administered as an injection into your eye by an eye doctor under a local anesthetic. Your doctor will decide the dose and frequency of the injection based on your disease condition. Do not self-administer the medicine.
Safety Advice
• Breast Feeding: Razumab 2.3mg injection should not be used in breastfeeding women because the medicine passes into the breast milk in small amounts and may harm your baby. Inform your physician if you are breastfeeding.
• Alcohol: It is unknown whether it is safe to consume alcohol while taking Razumab 2.3mg injection. Inform your physician if you are an alcoholic.
• Liver: It is unknown whether Razumab 2.3mg injection can be used in patients with liver disorders. Inform your physician if you have any liver disease before initiating the therapy.
• Lungs: It is unknown whether Razumab 2.3mg injection can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
• Driving: It is unsafe to drive after taking Razumab 2.3mg injection because it may cause temporary vision blurring. Do not drive or operate heavy machinery until the symptoms resolve.
• Pregnancy: Razumab 2.3mg injection should not be used during pregnancy because it may cause risk to the unborn child. Inform your physician if you are pregnant, suspecting pregnancy, or planning to get pregnant during the treatment. Use effective contraception during treatment and at least three months after the last dose.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.